OncoMatch/Clinical Trials/NCT05701306
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
Is NCT05701306 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including APG-115 and APG-2575 for neuroblastoma.
Treatment: APG-115 · APG-2575 — An open, non-randomized Phase I trial of dose-escalation and cohorts expansion to evaluate the safety, pharmacokinetic profile and initial efficacy of APG-115 alone or in combination with APG-2575 in the treatment of recurrent or refractory pediatric neuroblastoma or solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroblastoma
Tumor Agnostic
Prior therapy
Cannot have received: systemic antitumor therapy
Exception: placebo
Systemic antitumor therapy, including biotherapy, chemotherapy, surgery, radiotherapy, immunotherapy, and other investigational drug therapy (other than placebo), was received within 21 days prior to the first treatment with the study drug.
Cannot have received: small-molecule targeted drug therapy
Small-molecule targeted drug therapy was administered 14 days before the first treatment of the study drug or within a known five-half-life period, whichever is shorter.
Cannot have received: MDM2 inhibitor
Received MDM2 inhibitors
Cannot have received: BCL-2 inhibitor
Received ... BCL-2 inhibitors
Lab requirements
Blood counts
Kidney function
Liver function
Have adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify